ERIS vs GLAND: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. ERIS LIFESCIENCES shows a lower P/E and a higher net margin, while GLAND PHARMA shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ERIS leads 5; GLAND leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ERIS | GLAND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ERIS | GLAND |
|---|---|---|
| Live Price | ₹1,355.5 | ₹2,922.3 |
| Day Change | -0.08% | -0.83% |
| Volume | 24,968 | 3.89 L |
| 52-Week High | ₹1,740 | ₹3,042 |
| 52-Week Low | ₹1,200 | ₹1,573.6 |
| Distance from 52W High | -22.1% | -3.93% |
Valuation
| Metric | ERIS | GLAND |
|---|---|---|
| Market Cap | ₹18,777 Cr | ₹48,333 Cr |
| P/E Ratio | 28.98x | 42.78x |
| P/B Ratio | 4.81x | 4.66x |
| EPS | ₹10.28 | ₹22.09 |
| Book Value | ₹281.12 | ₹627.91 |
| Dividend Yield | 0.53% | 0.68% |
Growth
| Metric | ERIS | GLAND |
|---|---|---|
| Revenue Growth (TTM YoY) | 7.1% | 22.3% |
| EPS Growth (TTM YoY) | 200% | 96.4% |
| Qtr Sales Growth | 96.68% | -28.53% |
| Qtr Profit Growth | 196.73% | 14.96% |
Profitability & Leverage
| Metric | ERIS | GLAND |
|---|---|---|
| ROE | 7.64% | 12.02% |
| ROCE | 6.96% | 17.2% |
| Net Margin | 19.89% | 16.18% |
| Operating Margin | 29.73% | 38.8% |
| Debt to Equity | 0.65x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ERIS | GLAND |
|---|---|---|
| Promoter Holding | 54.14%▲ 0.22 pp | 51.77% |
| FII Holding | 5.75%▼ 0.64 pp | 8.74%▲ 1.44 pp |
| DII Holding | 20.72%▲ 0.37 pp | 30.44%▼ 2.91 pp |
| Public Holding | 19.4%▲ 0.07 pp | 9.05%▲ 1.53 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and GLAND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.